Experimental and clinical evidence is now available that antagonism of angiotensin II (Ang II) with both angiotensin-converting enzyme inhibitors and Ang II receptor antagonists (AIIAs) is effective in slowing the rate of renal functional loss in patients affected by proteinuric kidney diseases.Among AIIAs, telmisartan has been shown to be characterised by a potent and long lasting antihypertensive effect that may be associated with another specific effect of this molecule, the partial agonism of the peroxisome-activated receptor-gamma.Although this action has also been observed with other AIIAs, telmisartan seems to exert a more effective and specific action as in such a way to influence beneficially adipocyte metabolism, diabetes onset and insulin resistance. Recently, we have demonstrated, at the experimental and clinical level, that sustained blockade of Ang II biological activity with this class of compounds can potentially reduce the progression of renal dysfunction and in some circumstances induce the regression of renal functional and structural changes. In this review we analyse available experimental and clinical data that suggest that blocking Ang II with telmisartan may effectively ameliorate renal dysfunction in patients affected by the now frequently observed condition termed metabolic syndrome.
Brenner BMNephron adaptation to renal injury or ablation. Am J Physiol1985;249:F324-F337.
2.
Remuzzi A., Puntorieri S., Alfano M. et al. Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. Laboratory Investigation1992;67:572-9.
3.
Benigni A., Zoja C., Remuzzi G.The renal toxicity of sustained glomerular protein traffic. Laboratory Investigation1995;73:461-8.
4.
Benigni A., Remuzzi G.Glomerular protein trafficking and progression of renal disease to terminal uremia. Semin Nephrol1996;16:151-9.
5.
Remuzzi A., Gagliardini E., Donadoni C. et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int2002;62:885-94.
6.
Remuzzi G., Remuzzi A.Is regression of chronic nephropathies a therapeutic target?J Am Soc Nephrol2005;16:840-2.
7.
Remuzzi A., Gagliardini E., Sangalli F. et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int2006; 69:1124-30.
8.
Sharpe M., Jarvis B., Goa KLTelmisartan: a review of its use in hypertension. Drugs2001;61:1501-29.
9.
Kakuta H., Sudoh K., Sasamata M., Yamagishi S.Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers . Int J Clin Pharmacol Res2005;25:41-6.
10.
Battershill AJ, Scott LJTelmisartan: a review of its use in the management of hypertension. Drugs2006 ;66:51-83.
11.
Redon J., Luque-Otero M., Martell N., Chaves FJRenin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients . Pharmacogenomics J2005; 5:14-20.
12.
Karlberg BE , Lins LE, Hermansson K.Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens1999;17:293-302.
13.
Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension2004;43:993-1002.
14.
Schupp M., Janke J., Clasen R. et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation2004;109:2054-7.
15.
Sharma AMTelmisartan: the ACE of ARBs?Hypertension2006;47:822-3.
16.
Amerena J., Pappas S., Ouellet JP et al. ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res2002;30:543-52.
17.
Ragot S., Ezzaher A., Meunier A. et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens2002;16:865-73.
18.
Williams B., Gosse P., Lowe L., Harper R.The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens2006;24:193-200.
19.
Ingino C., Farsang C., Laucevicius A., Bergovec M.An open-label study investigating the efficacy and safety of 12-96 weeks of telmisartan treatment in patients with hypertension. J Int Med Res2003;31:561-74.
20.
Janke J., Engeli S., Gorzelniak K. et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes2002;51:1699-707.
21.
Sharma AMIs there a rationale for angiotensin blockade in the management of obesity hypertension?Hypertension2004;44:12-19.
22.
Engeli S., Bohnke J., Gorzelniak K. et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension2005; 45:356-62.
23.
Tang WHDo thiazolidinediones cause heart failure? A critical review. Cleve Clin J Med2006;73:390-7.
24.
Irons BK, Greene RS, Mazzolini TA et al. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy2006;26:168-81.
Willson TM, Brown PJ, Sternbach DD, Henke BRThe PPARs: from orphan receptors to drug discovery. J Med Chem2000;43:527-50.
27.
Sugimoto K. , Qi NR, Kazdova L. et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis . Hypertension2006;47:1003-09.
28.
Ouchi N., Kihara S., Funahashi T. et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation2003;107:671-4.
29.
Arita Y., Kihara S., Ouchi N. et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation2002;105:2893-8.
30.
Matsuda M., Shimomura I., Sata M. et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem2002 ;277:37487-91.
31.
Wassmann S. , Hilgers S., Laufs U. et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemiaassociated endothelial dysfunction. Arterioscler Thromb Vasc Biol2002;22:1208-12.
32.
Wassman S., Czech T., van Eickels M. et al. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein e/anglotensin II type 1a receptor double-knockout mice. Circulation2004;110:3062-7.
33.
Imanishi T. , Hano T., Nishio I.Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens2005;23:97-104.
34.
Fujimoto M. , Masuzaki H., Tanaka T. et al. An angiotensin II AT1-receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett2004;576:492-7.
35.
Fogari R., Lazzari P., Zoppi A.Effect of telmisartan losartan and lisinopril on insulin sensitivity in hypertensive patients with and without insulin resistance. Eur Heart J2004;25:78.
36.
Koulouris S. , Symeonides P., Triantafyllou K. et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol2005 ;95:1386-8.
37.
Remuzzi A., Perico N., Sangalli F. et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephrology. Am J Physiol1999;276:F457-66.
38.
Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001;345:861-9.
39.
Strippoli GF , Craig M., Craig JCAntihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev:CD004136, 2005.
40.
Ruggenenti P., Schieppati A., Remuzzi G.Progression, remission, regression of chronic renal diseases. Lancet2001;357:1601-08.
41.
Barnett A.Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol2006;17:S132-S135.
42.
Sugiyama H. , Kobayashi M., Wang DH et al. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant2005;20:2670-80.
